References
- Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin. Microbiol. Infect.14(Suppl.), 2–8 (2008).
- Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am.17, 479–501 (2003).
- Nagasawa Z, Kusaba K, Aoki Y. Susceptibility of clinical isolates of Pseudomonas aeruginosa in the Northern Kyushu district of Japan to carbapenem antibiotics, determined by an integrated concentration method: evaluation of the method based on Monte Carlo simulation. J. Infect. Chemother.14, 238–243 (2008).
- Ikawa K, Morikawa N, Uehara S et al. Pharmacokinetic–pharmacodynamic target attainment analysis of doripenem in infected patients. Int. J. Antimicrob. Agents33, 276–279 (2009).
- Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic–pharmacodynamic target attainment analyses to support Phase 2 and 3 dosing strategies for doripenem. Antimicrob. Agents Chemother.49, 3944–3947 (2005).
- Masterton R, Craven D, Rello J et al. Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development. J. Antimicrob. Chemother.60, 206–213 (2007).
- Rello J. Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia. Eur. Respir. Rev.16, 33–39 (2007).
- Siempos II, Vardakas KZ, Manta KG, Falagas ME. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur. Respir. J.29, 548–560 (2007).